Hims & Hers: Buy the Dip, Not the Panic
Hims & Hers (HIMS) plunged to 52-week lows after an FDA crackdown and a patent suit from Novo Nordisk over compounded semaglutide pills. The sell-off created a high-conviction trade: buy the oversold dip around $19.33 with a tight stop under the intraday low and a mid-term target near $28. The company still has a $4.4B market cap, positive free cas…